BioSpace News Archive

Fourth Quarter 2020 Revenue of Approximately $109.7 Million Full-Year 2020 Revenue of Approximately $362.0 Million Company to Present at J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 4:30 pm Eastern Time / 1:30 pm Pacific Time

Sosei Group Corporation, announced its Chief Financial Officer, Chris Cargill, will present at the 39th Annual J.P. Morgan Healthcare Conference, which will take place virtually, on Thursday, 14 January 2021.

Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells to treat cancers, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announce the signing of a clinical and commercial licensing agreement.

Second Genome, a leader in microbiome science, today announced that the company is presenting at the 13 th Annual Biotech Showcase Digital 2021 Conference this week. The conference is virtual and is occurring in parallel with the J.P. Morgan 39 th Annual Healthcare Conference 2021.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2020.

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has authorized incremental share repurchases of up to an additional $2 billion of the company’s outstanding shares of common stock.

The technology, developed by scientists at Memorial Sloan Kettering Cancer Center (“MSKCC”), headed by Dr. Michel Sadelain and Errant Gene Therapeutics, is a one-time treatment that inserts an encoded gene into a patient’s own bone marrow stem cells restoring the production of normal hemoglobin

Elanco Animal Health Incorporated announced that executive vice president of Transformation and Technology, Sarena Lin, will take a role outside of the company at the end of January.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials.

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations for its clinical product candidate, cavrotolimod (AST-008), for two development programs: